Y·Axis Bio brings experience on both sides of the deal table, analytical rigor, and direct capital-raising experience to the founders, companies, and investors navigating life sciences' most consequential moments.
Structured frameworks for ranking assets, programs, and BD opportunities — so leadership can make confident resource allocation decisions rather than debating on instinct.
Rigorous market assessment that goes beyond TAM slides — epidemiology, competitive landscape, pricing analogues, and payer dynamics, built to hold up in a partner or investor meeting.
Direct engagement with key opinion leaders and clinical experts to validate scientific hypotheses, understand clinical practice reality, and stress-test commercial assumptions before committing to a strategy or deal.
Deal economics and portfolio valuation built for real decisions — not just NPV outputs, but scenario analysis, sensitivity testing, and milestone structuring that reflects how deals actually get done.
From the analytical work that informs decisions to the execution that closes deals — across every stage of the engagement lifecycle.
Weighted scoring frameworks for ranking assets and BD opportunities — so teams allocate resources to what matters most.
Market sizing, competitive landscape, pricing analogues, and payer dynamics — built to hold up in partner and investor meetings.
Structured expert interviews to validate scientific and commercial assumptions before committing to a strategy or deal.
Deal NPV, scenario analysis, milestone structuring, and portfolio valuation — the quantitative backbone of every major decision.
Competitive positioning, portfolio strategy, M&A target identification, and board-level strategic advisory.
Deep-dive CI on pipeline activity, deal dynamics, and strategic positioning — actionable for senior leadership and boards.
Target identification, partner outreach strategy, and pipeline development — for both in-licensing and out-licensing mandates.
Scientific, commercial, and financial assessment of in-licensing or out-licensing opportunities — with modeling to back the view.
End-to-end BD process design — data room, CDA management, partner sequencing, and competitive tension management.
Deal economics design, milestone architecture, and royalty structuring — grounded in financial modeling and market comps.
Active negotiation support through term sheet to execution — with experience on both sides of the table informing every move.
Embedded BD function for companies that need senior leadership without a full-time hire — scalable up or down with your needs.
Matching your stage and story to the right capital instrument — institutional equity, non-dilutive, PIPE, or hybrid approaches.
Series A/B process management, investor targeting, narrative development, and data room prep through close — including PIPE and structured equity.
Strategy, writing support, and submission management for NIH, NSF, DoD, and other federal non-dilutive programs.
Identification and navigation of state economic development funds, life sciences-specific programs, and regional grants.
Early-stage investor targeting, pitch preparation, and process management for pre-institutional raises.
Capitalization modeling, use-of-proceeds planning, and valuation frameworks built for investor conversations.
Concept through incorporation — operating model, founding team strategy, IP structure, and early capital plan.
Asset in-licensing, spinout structuring, newco formation from academic or corporate IP, and venture creation from concept to capitalized.
Organizational structure, team formation, and operating rhythm design for early-stage and growth-stage companies.
Commercial launch planning, market entry strategy, and partner channel development for new products and markets.
Scaling playbook development, BD function buildout, and strategic planning for companies moving from early to growth stage.
Independent board roles with operating depth — BD, strategy, and capital experience informing governance at every stage.
Each engagement starts from a clear understanding of who you are and what you're actually trying to solve.
Deep operational experience running buy-side BD at Takeda — evaluating assets, structuring deals, and executing acquisitions across oncology and beyond. Understanding what pharma BD teams need to say yes, and how decisions actually get made internally.
Hands-on experience leading sell-side processes at bluebird bio, 2seventy bio, and GlycoEra — positioning assets for partnership, running competitive processes, and negotiating with large pharma counterparties from the other side of the table.
Greg Fralish, PhD founded Y·Axis Bio after 20+ years at the intersection of pharma and biotech — running buy-side BD at Takeda, leading sell-side processes at bluebird bio, 2seventy bio, and GlycoEra, and building companies from scratch as founder and CEO of Ziel Bio.
That experience spans more than $10B in transactions across dozens of deals, a $130M Series B financing, a $20M PIPE investment, and hands-on capital formation through SBIR grants, state funds, and angel investment — at organizations ranging from venture-backed startups to large-cap pharmaceutical companies.
The name reflects a simple idea: the Y-axis is the growth axis. That's the work. Based in Greater Boston. Available for retained engagements, project-based work, and board advisory roles.
>$10B across dozens of deals — buy-side at large pharma, sell-side at biotech, across licensing, collaborations, acquisitions & formations
$156M+ across Series B ($130M), PIPE ($20M), SBIR grants, state funds & angel investment
Portfolio prioritization · Commercial analysis · KOL engagement · Financial modeling
GlycoEra · bluebird bio / 2seventy bio · Takeda · Ziel Bio · UVA · Cato BioVentures
PhD, Biochemistry — University of Georgia · NIH NRSA Postdoctoral Fellow, Duke University
Most engagements begin with a direct conversation. Tell us where you are and what you're trying to solve — we'll be direct about whether and how Y·Axis Bio can help.
contact@yaxisbio.com linkedin.com/in/gregfralish